Concepts (206)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Haplotypes | 16 | 2022 | 119 | 2.130 |
Why?
|
| HIV-1 | 23 | 2022 | 1239 | 1.580 |
Why?
|
| HIV Infections | 30 | 2022 | 4946 | 1.490 |
Why?
|
| Genetic Variation | 8 | 2021 | 169 | 1.350 |
Why?
|
| Infectious Disease Transmission, Vertical | 12 | 2022 | 467 | 1.160 |
Why?
|
| Alleles | 12 | 2023 | 134 | 0.960 |
Why?
|
| HLA-C Antigens | 5 | 2017 | 15 | 0.870 |
Why?
|
| Gene Frequency | 13 | 2023 | 117 | 0.870 |
Why?
|
| Chemokine CCL3 | 4 | 2013 | 23 | 0.850 |
Why?
|
| Receptors, KIR | 6 | 2019 | 23 | 0.850 |
Why?
|
| Receptors, CCR5 | 7 | 2021 | 54 | 0.810 |
Why?
|
| Genetics, Population | 3 | 2021 | 50 | 0.790 |
Why?
|
| Polymorphism, Single Nucleotide | 12 | 2021 | 190 | 0.770 |
Why?
|
| Disease Resistance | 2 | 2021 | 6 | 0.750 |
Why?
|
| Interleukin-8 | 1 | 2021 | 21 | 0.740 |
Why?
|
| DNA, Viral | 9 | 2022 | 165 | 0.740 |
Why?
|
| Viremia | 3 | 2019 | 66 | 0.720 |
Why?
|
| HLA-B Antigens | 4 | 2017 | 12 | 0.690 |
Why?
|
| HLA-A Antigens | 3 | 2017 | 7 | 0.670 |
Why?
|
| Linkage Disequilibrium | 8 | 2021 | 40 | 0.650 |
Why?
|
| Gene Dosage | 4 | 2014 | 23 | 0.630 |
Why?
|
| Humans | 43 | 2023 | 14077 | 0.620 |
Why?
|
| Female | 30 | 2022 | 8751 | 0.600 |
Why?
|
| HLA Antigens | 3 | 2017 | 50 | 0.590 |
Why?
|
| RNA, Viral | 3 | 2019 | 303 | 0.580 |
Why?
|
| GTPase-Activating Proteins | 1 | 2017 | 3 | 0.560 |
Why?
|
| South Africa | 27 | 2022 | 7312 | 0.540 |
Why?
|
| Viral Load | 10 | 2022 | 808 | 0.530 |
Why?
|
| Anti-HIV Agents | 6 | 2022 | 1275 | 0.520 |
Why?
|
| Africa South of the Sahara | 5 | 2023 | 328 | 0.450 |
Why?
|
| Killer Cells, Natural | 5 | 2017 | 50 | 0.450 |
Why?
|
| Histocompatibility Antigens Class I | 3 | 2019 | 16 | 0.430 |
Why?
|
| Pharmacogenetics | 2 | 2023 | 27 | 0.420 |
Why?
|
| Receptors, IgG | 4 | 2022 | 28 | 0.420 |
Why?
|
| Adult | 17 | 2021 | 5664 | 0.420 |
Why?
|
| Genetic Predisposition to Disease | 8 | 2020 | 168 | 0.400 |
Why?
|
| Genotype | 10 | 2023 | 430 | 0.400 |
Why?
|
| Male | 17 | 2021 | 6489 | 0.400 |
Why?
|
| HLA-DRB1 Chains | 1 | 2011 | 17 | 0.390 |
Why?
|
| Chemokines, CC | 2 | 2008 | 15 | 0.380 |
Why?
|
| INDEL Mutation | 3 | 2014 | 16 | 0.370 |
Why?
|
| Geminiviridae | 2 | 2001 | 2 | 0.360 |
Why?
|
| Infant | 10 | 2022 | 2145 | 0.350 |
Why?
|
| Middle Aged | 9 | 2021 | 3425 | 0.340 |
Why?
|
| T-Lymphocytes | 2 | 2021 | 59 | 0.330 |
Why?
|
| Cohort Studies | 7 | 2021 | 939 | 0.280 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2022 | 60 | 0.280 |
Why?
|
| Disease Progression | 5 | 2019 | 154 | 0.260 |
Why?
|
| Nevirapine | 2 | 2019 | 146 | 0.250 |
Why?
|
| Case-Control Studies | 4 | 2022 | 464 | 0.240 |
Why?
|
| Polymerase Chain Reaction | 4 | 2014 | 260 | 0.240 |
Why?
|
| Molecular Sequence Data | 6 | 2014 | 263 | 0.220 |
Why?
|
| Nicotine | 1 | 2023 | 12 | 0.220 |
Why?
|
| 3' Untranslated Regions | 3 | 2019 | 9 | 0.220 |
Why?
|
| Young Adult | 6 | 2021 | 2357 | 0.220 |
Why?
|
| Infant, Newborn | 7 | 2022 | 1410 | 0.210 |
Why?
|
| Tobacco | 2 | 2001 | 14 | 0.210 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2022 | 9 | 0.210 |
Why?
|
| HIV Seropositivity | 2 | 2022 | 263 | 0.200 |
Why?
|
| Gene Expression Regulation | 3 | 2017 | 40 | 0.200 |
Why?
|
| Phylogeny | 2 | 2001 | 231 | 0.200 |
Why?
|
| Breast Feeding | 2 | 2020 | 119 | 0.200 |
Why?
|
| Plant Diseases | 3 | 2012 | 4 | 0.190 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2019 | 145 | 0.190 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2020 | 654 | 0.190 |
Why?
|
| Phytohemagglutinins | 1 | 2021 | 9 | 0.190 |
Why?
|
| Monocytes | 1 | 2021 | 27 | 0.190 |
Why?
|
| Base Sequence | 5 | 2014 | 149 | 0.180 |
Why?
|
| Polymorphism, Genetic | 5 | 2020 | 96 | 0.180 |
Why?
|
| Antigens, CD | 1 | 2020 | 23 | 0.170 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2020 | 73 | 0.170 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 46 | 0.170 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2019 | 11 | 0.170 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2019 | 7 | 0.160 |
Why?
|
| Pregnancy | 6 | 2022 | 1815 | 0.160 |
Why?
|
| Plants, Toxic | 1 | 1999 | 2 | 0.160 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2021 | 507 | 0.160 |
Why?
|
| Liver Failure | 1 | 2018 | 5 | 0.160 |
Why?
|
| Withholding Treatment | 1 | 2019 | 26 | 0.160 |
Why?
|
| Living Donors | 1 | 2018 | 20 | 0.160 |
Why?
|
| Chemoprevention | 1 | 2018 | 33 | 0.160 |
Why?
|
| DNA Copy Number Variations | 2 | 2021 | 19 | 0.150 |
Why?
|
| Liver Transplantation | 1 | 2018 | 53 | 0.150 |
Why?
|
| Marriage | 1 | 2017 | 5 | 0.140 |
Why?
|
| Receptors, Chemokine | 1 | 2017 | 6 | 0.140 |
Why?
|
| Receptors, Virus | 1 | 2017 | 5 | 0.140 |
Why?
|
| Alternative Splicing | 1 | 2017 | 4 | 0.140 |
Why?
|
| NF-kappa B | 1 | 2017 | 16 | 0.140 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2014 | 90 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 3 | 2011 | 180 | 0.130 |
Why?
|
| Anti-Retroviral Agents | 1 | 2021 | 542 | 0.130 |
Why?
|
| Chemokine CCL4 | 2 | 2014 | 14 | 0.130 |
Why?
|
| Aged | 5 | 2020 | 1650 | 0.120 |
Why?
|
| HLA-G Antigens | 1 | 2014 | 3 | 0.120 |
Why?
|
| Sequence Alignment | 2 | 2008 | 59 | 0.120 |
Why?
|
| Hypersensitivity | 1 | 2014 | 7 | 0.120 |
Why?
|
| Ferns | 1 | 2012 | 1 | 0.100 |
Why?
|
| Begomovirus | 1 | 2012 | 1 | 0.100 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2012 | 7 | 0.100 |
Why?
|
| CD4 Antigens | 1 | 2012 | 47 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 36 | 0.100 |
Why?
|
| Mothers | 3 | 2020 | 190 | 0.100 |
Why?
|
| Ligands | 1 | 2011 | 33 | 0.090 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 1 | 2011 | 49 | 0.090 |
Why?
|
| Lysogeny | 1 | 2010 | 2 | 0.090 |
Why?
|
| Bacteriophages | 1 | 2010 | 4 | 0.090 |
Why?
|
| Lactobacillus | 1 | 2010 | 7 | 0.090 |
Why?
|
| Vagina | 1 | 2010 | 91 | 0.090 |
Why?
|
| Amelogenin | 1 | 2008 | 3 | 0.080 |
Why?
|
| Sex Determination by Skeleton | 1 | 2008 | 3 | 0.080 |
Why?
|
| Sex Determination Analysis | 1 | 2008 | 5 | 0.080 |
Why?
|
| India | 2 | 2017 | 60 | 0.070 |
Why?
|
| HIV Antibodies | 2 | 2019 | 243 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2019 | 43 | 0.070 |
Why?
|
| Viral Proteins | 2 | 2004 | 30 | 0.060 |
Why?
|
| Lymphocyte Activation | 2 | 2017 | 40 | 0.060 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 2008 | 16 | 0.060 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2004 | 7 | 0.060 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2004 | 8 | 0.060 |
Why?
|
| Conserved Sequence | 1 | 2004 | 10 | 0.060 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2004 | 12 | 0.060 |
Why?
|
| Gene Products, gag | 1 | 2004 | 11 | 0.060 |
Why?
|
| HIV Seronegativity | 2 | 2019 | 52 | 0.060 |
Why?
|
| Cytochrome P-450 CYP2A6 | 1 | 2023 | 3 | 0.060 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2023 | 16 | 0.060 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 2 | 2019 | 20 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 210 | 0.050 |
Why?
|
| Gene Duplication | 1 | 2022 | 13 | 0.050 |
Why?
|
| Phenotype | 1 | 2022 | 144 | 0.050 |
Why?
|
| Agrobacterium tumefaciens | 1 | 2001 | 1 | 0.050 |
Why?
|
| Transformation, Genetic | 1 | 2001 | 4 | 0.050 |
Why?
|
| Lycopersicon esculentum | 1 | 2001 | 2 | 0.050 |
Why?
|
| Molecular Weight | 1 | 2001 | 13 | 0.050 |
Why?
|
| Cloning, Molecular | 1 | 2001 | 26 | 0.050 |
Why?
|
| Open Reading Frames | 1 | 2001 | 16 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 237 | 0.050 |
Why?
|
| Kinetics | 1 | 2020 | 65 | 0.040 |
Why?
|
| GPI-Linked Proteins | 1 | 2020 | 5 | 0.040 |
Why?
|
| South America | 1 | 2020 | 26 | 0.040 |
Why?
|
| Receptors, KIR3DL1 | 1 | 2019 | 5 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2019 | 80 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2019 | 10 | 0.040 |
Why?
|
| Mexico | 1 | 1999 | 3 | 0.040 |
Why?
|
| Africa, Southern | 2 | 2012 | 89 | 0.040 |
Why?
|
| Human Genome Project | 1 | 2018 | 6 | 0.040 |
Why?
|
| DNA | 2 | 2011 | 73 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2019 | 25 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2019 | 24 | 0.040 |
Why?
|
| Species Specificity | 1 | 1999 | 49 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2018 | 20 | 0.040 |
Why?
|
| Evolution, Molecular | 1 | 1999 | 60 | 0.040 |
Why?
|
| Geography | 1 | 1999 | 60 | 0.040 |
Why?
|
| Zimbabwe | 1 | 1999 | 115 | 0.040 |
Why?
|
| Cytokines | 1 | 2019 | 107 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 163 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2018 | 175 | 0.040 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2017 | 6 | 0.040 |
Why?
|
| Interleukin-2 | 1 | 2017 | 22 | 0.040 |
Why?
|
| Receptors, CXCR6 | 1 | 2017 | 3 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2017 | 39 | 0.040 |
Why?
|
| Age Factors | 1 | 2018 | 364 | 0.030 |
Why?
|
| AIDS Vaccines | 1 | 2018 | 150 | 0.030 |
Why?
|
| Environmental Exposure | 1 | 2017 | 45 | 0.030 |
Why?
|
| Time Factors | 1 | 2018 | 503 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2018 | 867 | 0.030 |
Why?
|
| HIV | 1 | 2018 | 380 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2013 | 5 | 0.030 |
Why?
|
| Risk | 1 | 2013 | 87 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2018 | 1675 | 0.030 |
Why?
|
| Indian Ocean Islands | 1 | 2012 | 1 | 0.030 |
Why?
|
| Africa, Eastern | 1 | 2012 | 16 | 0.030 |
Why?
|
| Child | 1 | 2019 | 2180 | 0.030 |
Why?
|
| CD56 Antigen | 1 | 2012 | 5 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2012 | 65 | 0.030 |
Why?
|
| DNA Primers | 1 | 2011 | 55 | 0.020 |
Why?
|
| Receptors, KIR2DL1 | 1 | 2011 | 5 | 0.020 |
Why?
|
| Aging | 1 | 2012 | 109 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2013 | 325 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 41 | 0.020 |
Why?
|
| Prophages | 1 | 2010 | 3 | 0.020 |
Why?
|
| Vaginal Discharge | 1 | 2010 | 3 | 0.020 |
Why?
|
| DNA, Ribosomal | 1 | 2010 | 9 | 0.020 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2010 | 18 | 0.020 |
Why?
|
| Virion | 1 | 2010 | 12 | 0.020 |
Why?
|
| Vaginosis, Bacterial | 1 | 2010 | 19 | 0.020 |
Why?
|
| DNA, Bacterial | 1 | 2010 | 53 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2010 | 20 | 0.020 |
Why?
|
| Paleontology | 1 | 2008 | 3 | 0.020 |
Why?
|
| Chromosomes, Human, X | 1 | 2008 | 3 | 0.020 |
Why?
|
| Forensic Genetics | 1 | 2008 | 3 | 0.020 |
Why?
|
| Chromosomes, Human, Y | 1 | 2008 | 9 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2008 | 38 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 1377 | 0.020 |
Why?
|
| Mitogens | 1 | 2006 | 4 | 0.020 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2006 | 4 | 0.020 |
Why?
|
| Chemokine CCL5 | 1 | 2006 | 9 | 0.020 |
Why?
|
| Fetal Blood | 1 | 2006 | 27 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2006 | 54 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2004 | 6 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2004 | 22 | 0.010 |
Why?
|
| Epitope Mapping | 1 | 2004 | 31 | 0.010 |
Why?
|
| HIV Antigens | 1 | 2004 | 26 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 2004 | 26 | 0.010 |
Why?
|
| Protein Binding | 1 | 2004 | 62 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2004 | 36 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2004 | 139 | 0.010 |
Why?
|